Cerebriu Apollo Brain

Cerebriu

Cerebriu has developed Apollo, a protocol technology aimed at optimizing brain MRI scan acquisition and patient management. It exists of MR Smart Protocol and MR Smart Alert.
MR Smart Protocol analyses an initial abbreviated set of images and suggests the most appropriate next sequences based on initial findings.
MR Smart Alert detects critical finding at the earliest stages of the MRI examination for the prioritization of radiological review and notification of critical findings to the care team.
Product specifications Information source: Vendor
Last updated: Oct. 28, 2023
General
Product name Cerebriu Apollo Brain
Company Cerebriu
Subspeciality Neuro
Modality MR
Disease targeted Infarcts (except chronic), intracranial tumors (except iso-intense on T2 FLAIR), and intracranial hemorrhages (except isolated intraventricular hemorrhages, microhemorrhages, or those that are not hypointense on SWI/T2* GRE).
Key-features Vizualization of criticial brain pathology candidate findings, real-time results enabling MR protocol adaptation
Data characteristics
Population Patients between 15 and 75 years receiving brain MR
Input FLAIR, diffusion, T2*/SWI or equivalent
Input format DICOM
Output Detection of candidates finding larger than 5 mm3, image annotations
Output format DICOM SC
Technology
Integration Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased, Embedded on the MRI console
Deployment Locally on dedicated hardware, Cloud-based, Hybrid solution
Trigger for analysis Automatically, while the patient is in the scanner
Processing time 1 - 10 minutes
Certification
CE
Certified, Class I , MDD
FDA
No or not yet
Intended use statements
Intended use (according to CE) Cerebriu Apollo for Brain MRI is intended for automatic labeling and visualization of candidate findings larger than 5 mm3 from a set of magnetic resonance image (MRI) scans of a human brain aged between 15 and 75 years. The supported candidate findings are [infarcts] (except chronic), [intracranial tumors] (except iso-intense on T2 FLAIR), and [intracranial hemorrhages] (except isolated intraventricular hemorrhages, microhemorrhages, or those that are not hypointense on SWI/T2* GRE).
Market presence
On market since 05-2021
Distribution channels
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Subscription
Based on Number of users, Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance

  • Diagnostic Test Accuracy Study of a Commercially Available Deep Learning Algorithm for Ischemic Lesion Detection on Brain MRIs in Suspected Stroke Patients from a Non-Comprehensive Stroke Center (read)

Non-peer reviewed papers on performance
Other relevant papers